Jay Bradner

Jay Bradner, President of the Novartis Institute for BioMedical Research, reveals cutting-edge advancements in drug development. He discusses the challenges of targeting 'undruggable' proteins and how innovative techniques like molecular glues and gene therapies are revolutionizing therapeutic possibilities. Bradner shares breakthroughs focused on previously inaccessible targets, like SHIP2, and emphasizes the importance of collaboration in this field. Insights into the science behind drug discovery shine a light on the future of treatment for serious diseases.